Free tool
FAERS Monitor: Nucynta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203794 or its brand name (Nucynta, Tapentadol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
28,531
Serious
26,313
92% of reports
Hospitalization
3,126
Death reported
19,844
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death11,509
- toxicity to various agents9,269
- overdose5,778
- drug abuse1,400
- drug dependence962
- drug withdrawal syndrome neonatal916
- accidental overdose656
- drug ineffective583
- pain485
- nausea443
- intentional product misuse350
- fatigue281
- dizziness268
- headache256
- fall230
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 95 |
| 2010 | 142 |
| 2011 | 287 |
| 2012 | 283 |
| 2013 | 213 |
| 2014 | 233 |
| 2015 | 709 |
| 2016 | 819 |
| 2017 | 2,271 |
| 2018 | 21,364 |
| 2019 | 458 |
| 2020 | 386 |
| 2021 | 239 |
| 2022 | 245 |
| 2023 | 245 |
| 2024 | 281 |
| 2025 | 215 |
| 2026 | 44 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,628 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug withdrawal syndrome neonatalSignal | 916 | 48.5 | 45.5 | 40,003 |
| toxicity to various agentsSignal | 9,269 | 42.8 | 42.1 | 360,597 |
| overdoseSignal | 5,778 | 20.3 | 19.8 | 104,019 |
| accidental overdoseSignal | 656 | 13.4 | 12.5 | 7,421 |
| drug abuseSignal | 1,400 | 12.6 | 12.0 | 14,738 |
| deathSignal | 11,509 | 10.0 | 9.8 | 95,521 |
| drug dependenceSignal | 962 | 4.4 | 4.2 | 2,557 |
| intentional product misuseSignal | 350 | 3.0 | 2.7 | 451 |
| pain | 485 | 0.6 | 0.5 | 150 |
| fall | 230 | 0.5 | 0.4 | 110 |
| nausea | 443 | 0.4 | 0.4 | 385 |
| dizziness | 268 | 0.4 | 0.4 | 252 |
| drug ineffective | 583 | 0.3 | 0.3 | 867 |
| headache | 256 | 0.3 | 0.3 | 428 |
| fatigue | 281 | 0.3 | 0.2 | 591 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.